Compare Agilent Technologies Inc (A) vs Alibaba Group (BABA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Alibaba Group — how do they compare? Agilent Technologies Inc trades at $129.08 (market cap $37.04B), while Alibaba Group trades at $109.5 (market cap $234.34B). The key difference: Alibaba Group is far larger — about 6.3× Agilent Technologies Inc's market cap, and Alibaba Group pays the higher dividend (1.07%). Which is the better fit depends on your goals.
| A | BABA | |
|---|---|---|
Market Cap | $37.04B | $234.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $189.34 |
52-Week Low | $110.24 | $94.83 |
Enterprise Value | $38.59B | $229.16B |
Dividend Yield | 0.78% | 1.07% |
Volume | — | 18,069,938 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Alibaba (BABA) trades at $98.14, up 2.08% today, but remains in a bearish technical trend with recent earnings misses. The company reported strong revenue growth to $996.35B in 2025 and a net income margin of 13.05%, yet faces headwinds from regulatory investigations and a $600M DOJ settlement. Analyst consensus is overwhelmingly bullish with an $195 price target, highlighting a significant discount to intrinsic value despite near-term challenges.
The stock presents a contrarian opportunity with attractive valuations (P/E 15.13, P/S 1.56) amid pessimism. Key risks include ongoing legal probes, AI competition, and macroeconomic pressures. Upside depends on earnings recovery and resolution of regulatory overhangs, making it a high-risk, high-reward play for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →
